Topical Drug-induced Subacute Cutaneous Lupus Erythematosus Isolated to the Hands
Overview
Rheumatology
Authors
Affiliations
Subacute cutaneous lupus erythematosus (SCLE) is a well-defined subtype of lupus erythematosus, characterised by photosensitivity, annular and/or psoriasiform lesions, variable systemic involvement and presence of circulating SSA/anti-Ro antibodies. SCLE may be idiopathic or drug-induced. Both the idiopathic and drug-induced forms of SCLE are analogous in their clinical, serological and histological features. Drug-induced SCLE has been reported with various oral agents, but to our knowledge this is the first reported case due to a topical medication. A 34-year-old female foot masseuse presented with a 2-month history of scaly, erythematous lesions isolated to the dorsal hands and interdigital spaces. She had used topical terbinafine, a topical antifungal cream, to her clients' feet for a number of years. ANA and anti-SSA/Ro antibodies were positive. Physical examination, serology and histopathology were consistent with SCLE. We propose that our patient's unique presentation of SCLE may be explained by a prolonged occupational exposure to topical terbinafine as a foot masseuse. While oral terbinafine is a drug known to cause drug-induced SCLE, to our knowledge, this is the first topically induced form of the disease.
Kowalska J, Rok J, Rzepka Z, Wrzesniok D Pharmaceuticals (Basel). 2021; 14(8).
PMID: 34451820 PMC: 8401619. DOI: 10.3390/ph14080723.
Drug-induced lupus erythematosus: an update on drugs and mechanisms.
He Y, Sawalha A Curr Opin Rheumatol. 2018; 30(5):490-497.
PMID: 29870500 PMC: 7299070. DOI: 10.1097/BOR.0000000000000522.